Adagene Inc. (ADAG) stock

ADAGNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 1, 2026Score 5/30

$1.71−0.29 (-14.50%)

Close on Nov 13, 2026Market cap $101.29MP/E –Yield –

Adagene ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

For fiscal 2025 it was -$21.00M. The highest annual figure on record is -$16.43M in fiscal 2018.

Annual ebitda

Period	Period end	Value	Change
FY2025	Dec 31, 2025	-$21.00M	–
FY2024	Dec 31, 2024	-$35.23M	–
FY2023	Dec 31, 2023	-$22.74M	–
FY2022	Dec 31, 2022	-$82.77M	–
FY2021	Dec 31, 2021	-$71.24M	–
FY2020	Dec 31, 2020	-$42.29M	–
FY2019	Dec 31, 2019	-$18.35M	–
FY2018	Dec 31, 2018	-$16.43M	–

Where these numbers come from

Parsed from the XBRL in Adagene's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ADAG.

Compare: ADAG vs CBIO · ADAG vs APLM · ADAG vs IMNM · ADAG vs CTMX · ADAG vs BOLT

Revenue growth7332.8% · median -63.3%

Operating margin-279.5% · median -1157.3%

Net margin-229.6% · median -881.0%

Company	Revenue	Growth
CBIO	$15.00M	–
CTMX	$14.03M	-87.7%
ADAG	$7.67M	+7332.8%
IMNM	$4.02M	-63.3%
BOLT	$2.53M	-51.3%
APLM	–	–

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 128
Held by institutions: 32.5%
Auditor: PricewaterhouseCoopers Zhong TianLLP
SEC CIK: 1818838

Advertisement
300 × 250

See a number that looks wrong?